Becton Dickinson has delivered a strong share price run over the past year, which puts fresh focus on whether the current US$200.42 level is grounded in the cash it can generate. For anyone looking at the stock today, the central issue is how that recent performance lines up with the cash flow profile implied by its existing business.
-
The share price return of 40.1% over the past year puts real pressure on the question of whether the valuation still lines up with the cash the business can produce.
-
Becton Dickinson relies heavily on recurring demand for medical devices and consumables, which can support relatively steady cash inflows and gives investors a clearer line of sight on future funding needs.
-
If you'd rather focus on earnings, this one's for you. See why Becton Dickinson's 33.1x P/E tells a different valuation story .
The issue now is whether that recent share price performance is fully supported by what Becton Dickinson's cash flows imply when valued using a Discounted Cash Flow model.
If you want a wider watchlist of ideas built around clear cash flow and valuation checks, a focused screener such as 29 high quality undervalued stocks can be a useful next stop in your research.
Does Becton Dickinson Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) approach here is built around what Becton Dickinson can return to shareholders in cash over time. Latest twelve month free cash flow sits at about $2.6b, and the 2 Stage Free Cash Flow to Equity model assumes that this pool of cash continues to grow rather than shrink.
Projected free cash flow is expected to move into the low $3b range by 2030, with earlier years guided by analyst inputs and later years by more moderate extension estimates. That kind of profile fits a mature healthcare supplier where recurring demand for devices and consumables underpins the model instead of aggressive expansion bets. The DCF output points to an intrinsic value that is modestly above the current $200.42 share price, so the model implies some remaining support from cash flows at today's level. Find out what Becton Dickinson could be worth using our Discounted Cash Flow (DCF) estimate .
The Becton Dickinson Narrative: What Would Justify Today's Price?
Narratives pick up where the Becton Dickinson valuation puzzle leaves off and spell out what path for future growth, profitability and earnings would need to hold for the stock to end up worth materially more or materially less than today's price. Each narrative anchors its number to a clear view on where Becton Dickinson's growth, margins and risk profile might go next. This gives you a reference point you can return to as new information comes through.
Community views on Becton Dickinson are split between those who see extra upside in the current platforms and those who think much of that story is already reflected in the price.
Bull case: 11% undervalued
"The build out of GLP 1 related biologic delivery agreements, now spread across roughly 100 customer programs, sets up an installed base…"
Discover why this Narrative puts Becton Dickinson at 11% undervalued .
Bear case: roughly fairly valued
"Persistent weakness in China, where revenue is currently declining around 10% and is expected to represent only about 3% to 4% of Becton Dickinson…"
Explore why this Narrative puts Becton Dickinson at roughly fairly valued .
The one Becton Dickinson check this valuation has not answered
Cash flow models only tell you what the business could be worth. They do not show who is steering Becton Dickinson or how their pay shapes the decisions that create those numbers. See who runs Becton Dickinson and how they are paid .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BDX .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

